



R&D PORTFOLIO PLANNING & ANALYTICS

LIFE SCIENCES SOLUTION POWERED BY ANAPLAN

Efficient and effective accelerator to improve automation, transparency and traceability in Life Sciences R&D Finance cycles

Business Challenge

R&D Portfolio Planning is critical to enabling optimal strategic decisions for any Life Sciences company. While uncertainty is natural when it comes to navigating clinical trials and FDA regulations, inefficient R&D investment analysis processes make it even more difficult for companies to make informed decisions.

Top challenges organizations face include:

1. Ineffective methods in evaluating and comparing investments in the R&D pipeline – projects which are ‘first to the trough’ usually get R&D investment.
2. Lack of transparency and traceability in the R&D Portfolio – inability to understand the realization of the business case from prior R&D investments.
3. Limited automated analytics capabilities to generate insights when planning assumptions change.
4. Inefficient collaboration in integrating the R&D Portfolio Planning process with broader Enterprise Planning processes.
5. Lack of a robust end-to-end governance process and a cross-functional workflow throughout the R&D Portfolio Planning lifecycle.

Opportunities & Expectations

Life Sciences portfolio and decision analysis is a complex endeavor that evolves over the lifecycle of an asset. Companies aspire to have outstanding visibility, traceability, and analytical capabilities in the R&D portfolio investment decision making process.



Evaluate and understand all possible R&D investments for funding in the pipeline, then allocate funding to the best investments based on comprehensive comparisons.



Take a prospective and historical lens when reviewing investments leveraging data-driven insights from past investment decisions.



Deploy automated analytics tools to drive scenario analysis and modeling to compare investments and capital allocation throughout all stages of clinical trials.



Connect the R&D planning process with broader Enterprise Business Planning Activities and enable transparency and consistency in the translation to operational strategy.




Establish standardized processes to consistently govern and drive streamlined workflow and successful decision making.

Overview of the R&D Portfolio Planning & Analytics Solution


Deloitte’s solution powered by Anaplan can address the challenges and significantly improve efficiency of the R&D finance lifecycle.

Deloitte’s proprietary R&D Portfolio Planning & Analytics solution has a series of distinct capabilities in predictive analytics, portfolio value management and workflow automation to allow businesses to have an improved R&D portfolio analysis process. The solution enhances analytical capabilities and enables performance insights by leveraging real-time data tracking, scenario and sensitive analyses, and data visualization. It also helps cross-functional collaboration and increases transparency in R&D Portfolio Planning through seamless integration with enterprise level long-range planning. The R&D Portfolio Planning team will be empowered with a more systematically governed process, more robust statistical analyses, and enhanced decision-making capabilities.



Features & Benefits of the Life Sciences R&D Portfolio Planning & Analytics Solution

Deloitte's R&D Portfolio Planning & Analytics solution powered by Anaplan provides a robust set of functionality to provide enhanced insights, improve the decision-making process and optimize capital allocation.



* PrecisionView™ is Deloitte's proprietary advanced forecasting solution powered by Anaplan and Google Cloud, AWS or Azure.

START THE CONVERSATION

Diane Ma
Principal
Deloitte Consulting LLP
dima@deloitte.com
+1213 553 1221

Jamie Weidner
Managing Director
Deloitte Consulting LLP
jweidner@deloitte.com
+1 212 618 4268

Kevin Hogan
Senior Manager
Deloitte Consulting LLP
kevhogan@deloitte.com
+1 415 783 6831

This communication contains general information only, and none of Deloitte Touche Tohmatsu Limited, its member firms or their related entities (collectively, the "Deloitte Network"), is, by means of this communication, rendering professional advice or services. Before making any decisions or taking any action that may affect your finances, or your business, you should consult a qualified professional adviser. No entity in the Deloitte Network shall be responsible for any loss whatsoever sustained by any person who relies on this communication.

As used in this document, "Deloitte" means Deloitte Consulting LLP, a subsidiary of Deloitte LLP. Please see www.deloitte.com/us/about for a detailed description of the legal structure of Deloitte USA LLP, Deloitte LLP.

Copyright © 2024 Deloitte Development LLC. All rights reserved.